$See \ discussions, stats, and \ author \ profiles \ for \ this \ publication \ at: \ https://www.researchgate.net/publication/379445812$

Impact of Breastfeeding on Infant Immune Responses in the Context of HIV

Article · March 2024

CITATIONS		READS	
17		386	
2 authors:			
	Emmanuel Ifeanyi Obeagu		Getrude Uzoma Obeagu
	Kampala International University (KIU)	\sim	Kampala International University (KIU)
	1,686 PUBLICATIONS 23,400 CITATIONS		534 PUBLICATIONS 10,607 CITATIONS
	SEE PROFILE		SEE PROFILE

Impact of Breastfeeding on Infant Immune Responses in the Context of HIV

*Emmanuel Ifeanyi Obeagu¹ and Getrude Uzoma Obeagu²

¹Department of Medical Laboratory Science, Kampala International University, Uganda

²School of Nursing Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, <u>Department of Medical Laboratory Science</u>, <u>Kampala International University</u>, <u>Uganda</u>, <u>emmanuelobeagu@yahoo.com</u>, <u>ORCID</u>: 0000-0002-4538-0161

Abstract

Breastfeeding remains a cornerstone of infant nutrition, providing essential nutrients and immunological benefits critical for infant health and development. However, in the context of HIV infection, the decision to breastfeed poses significant challenges due to the risk of mother-to-child transmission of the virus. This review explores the complex interplay between breastfeeding and infant immune responses in the context of HIV infection, with a focus on the impact of breastfeeding on infant health outcomes and HIV transmission risk. We examine current evidence on the immunological components of breast milk, including antibodies, cytokines, and other bioactive factors, and their role in shaping infant immune responses and protection against infections. Additionally, we discuss strategies to mitigate HIV transmission risk during breastfeeding, including antiretroviral therapy, exclusive breastfeeding, and infant pre-exposure prophylaxis. Understanding the immunological implications of breastfeeding in the context of HIV infection is essential for guiding clinical practice and informing public health policies aimed at optimizing infant feeding practices while minimizing HIV transmission risk.

Keywords: Breastfeeding, Infant Immune Responses, HIV, Maternal Transmission, Antiretroviral Therapy, Breast Milk Composition

Introduction

Breastfeeding is universally recognized as the optimal mode of infant feeding, providing a unique blend of nutrients, growth factors, and immunological components essential for infant growth, development, and immune system maturation. Breast milk contains a myriad of bioactive factors, including antibodies, cytokines, growth factors, and antimicrobial peptides, which confer passive **Citation**: Obeagu EI, Obeagu GU. Impact of Breastfeeding on Infant Immune Responses in the Context of HIV. Elite Journal of Nursing and Health Science, 2024; 2(4):23-39

and active protection against infections and support the development of the infant's immune system. However, in the context of HIV infection, breastfeeding presents a complex dilemma due to the risk of mother-to-child transmission (MTCT) of the virus through breast milk. The decision to breastfeed in HIV-infected mothers must balance the nutritional and immunological benefits of breastfeeding against the risk of HIV transmission to the infant. HIV can be transmitted from mother to child during pregnancy, childbirth, and breastfeeding, with breastfeeding accounting for a significant proportion of pediatric HIV infections in resource-limited settings where safe alternatives to breastfeeding are limited. Despite advances in prevention of mother-to-child transmission (PMTCT) interventions, including antiretroviral therapy (ART) and infant prophylaxis, the risk of HIV transmission through breastfeeding remains a critical concern. Understanding the impact of breastfeeding on infant immune responses in the context of HIV infection is essential for guiding clinical decision-making and informing public health policies aimed at reducing MTCT while promoting infant health and well-being.¹⁻²⁵

Breast milk is a complex biological fluid that plays a crucial role in shaping the infant's immune system and providing protection against infections. Immunological components of breast milk, such as secretory IgA antibodies, lactoferrin, lysozyme, and human milk oligosaccharides, contribute to passive immunity by preventing pathogen attachment to mucosal surfaces and neutralizing microbial toxins. Additionally, breast milk contains various cytokines and growth factors that modulate immune cell function and promote the development of a balanced and responsive immune system in the infant. Understanding the dynamic interplay between breastfeeding and infant immune responses is essential for optimizing infant feeding practices and reducing the risk of infectious diseases in HIV-exposed infants. In the era of lifelong ART for HIV-infected individuals, the management of HIV in the breastfeeding mother-infant dyad has evolved significantly. Effective ART suppresses maternal viral load, reducing the risk of HIV transmission to the infant during breastfeeding. Moreover, maternal ART has been shown to alter the composition of breast milk, reducing HIV RNA levels and potentially mitigating the risk of transmission. Strategies such as exclusive breastfeeding, where the infant receives only breast milk and no other fluids or foods, and infant prophylaxis with antiretroviral medications further reduce the risk of MTCT while maximizing the nutritional and immunological benefits of breastfeeding. However, challenges remain in ensuring universal access to ART and PMTCT services, particularly in resource-limited settings, where infrastructure, resources, and healthcare access may be limited.²⁶⁻⁵⁵

Breastfeeding and Infant Immune Development

Breastfeeding plays a pivotal role in shaping infant immune development, providing a unique blend of bioactive components that support the maturation and function of the infant's immune system. The immunological benefits of breast milk extend far beyond basic nutrition, encompassing passive and active mechanisms that confer protection against infections and promote optimal immune responses in the developing infant. One of the key immunological components of breast milk is secretory immunoglobulin A (sIgA), which provides passive immunity by coating mucosal surfaces in the gastrointestinal and respiratory tracts, preventing the attachment and invasion of pathogens. sIgA antibodies in breast milk are specific to antigens **Citation**: Obeagu EI, Obeagu GU. Impact of Breastfeeding on Infant Immune Responses in the Context of HIV. Elite Journal of Nursing and Health Science, 2024; 2(4):23-39

encountered by the mother, providing tailored protection against local pathogens in the infant's environment. Additionally, breast milk contains other immunoglobulins such as IgG and IgM, as well as complement proteins, which further enhance the infant's immune defenses against a wide range of infectious agents.⁵⁶⁻⁵⁷

Furthermore, breast milk is rich in cytokines, chemokines, growth factors, and antimicrobial peptides that modulate immune cell function, promote the development of a balanced immune response, and support tissue repair and regeneration. For example, transforming growth factorbeta (TGF-B) in breast milk helps regulate mucosal immune responses, while lactoferrin and lysozyme exert antimicrobial effects against bacteria and viruses, bolstering the infant's innate immune defenses. Human milk oligosaccharides (HMOs), complex carbohydrates found in breast milk, serve as prebiotics that selectively promote the growth of beneficial gut bacteria, contributing to the development of a healthy gut microbiome and immune system. Breastfeeding also facilitates the transfer of maternal immune cells, such as lymphocytes and macrophages, to the infant, providing additional protection against infections and enhancing immune surveillance. These maternal immune cells educate the infant's immune system, helping to shape its repertoire of immune cells and responses. Moreover, breastfeeding promotes bonding between mother and infant, which has been shown to have immunomodulatory effects, reducing stress and promoting the release of oxytocin and other hormones that enhance immune function. The immunological benefits of breastfeeding are particularly crucial in the context of HIV-exposed infants, where the risk of HIV transmission through breast milk must be balanced against the protective effects of breastfeeding on infant health and immune development. Strategies such as exclusive breastfeeding, where the infant receives only breast milk and no other fluids or foods, combined with maternal antiretroviral therapy (ART) and infant prophylaxis, have been shown to reduce the risk of mother-to-child transmission (MTCT) of HIV while maximizing the immunological benefits of breastfeeding.58-79

Risk of HIV Transmission Through Breast Milk

The risk of HIV transmission through breast milk is a critical concern in the context of mother-tochild transmission (MTCT) of HIV, particularly in regions with limited access to safe alternatives to breastfeeding. Breast milk serves as a potential route of HIV transmission from an HIV-infected mother to her infant, posing significant challenges for infant feeding practices and HIV prevention strategies. Several factors contribute to the risk of HIV transmission through breast milk, including maternal viral load, duration of breastfeeding, and integrity of the infant's gastrointestinal mucosa. Maternal factors such as high viral load, advanced HIV disease stage, and presence of mastitis or breast lesions increase the likelihood of HIV transmission through breast milk. Conversely, effective antiretroviral therapy (ART) suppresses maternal viral load, reducing the risk of HIV transmission to the infant during breastfeeding. The duration of breastfeeding also influences the risk of HIV transmission, with longer durations of breastfeeding associated with a higher cumulative risk of MTCT. Exclusive breastfeeding, where the infant receives only breast milk and no other fluids or foods, has been shown to reduce the risk of HIV transmission compared to mixed feeding practices, which involve supplementation with other fluids or foods. However, prolonged

breastfeeding beyond six months increases the risk of HIV transmission, highlighting the importance of balancing the benefits of breastfeeding with the risk of HIV acquisition.⁸⁰⁻⁹⁹

The integrity of the infant's gastrointestinal mucosa plays a crucial role in determining susceptibility to HIV infection through breast milk. Breast milk contains various immunological factors, such as secretory IgA antibodies, lactoferrin, and lysozyme, which provide passive immunity and protect against infections. Additionally, maternal immune cells present in breast milk may contribute to immune education and protection against HIV transmission. However, factors such as preterm birth, low birth weight, and gastrointestinal infections may compromise the integrity of the infant's mucosal barrier, increasing susceptibility to HIV infection. Strategies to mitigate the risk of HIV transmission through breast milk include maternal ART, infant prophylaxis, and adherence to infant feeding guidelines recommended by the World Health Organization (WHO). Maternal ART suppresses maternal viral load, reducing the concentration of HIV in breast milk and decreasing the risk of MTCT. Infant prophylaxis with antiretroviral medications, such as nevirapine or zidovudine, further reduces the risk of HIV acquisition during breastfeeding. Exclusive breastfeeding for the first six months of life, followed by introduction of complementary foods and continued breastfeeding up to 12 months or longer with appropriate complementary feeding, is recommended for HIV-exposed infants in resource-limited settings where safe alternatives to breastfeeding are not readily available.¹⁰⁰⁻¹²²

Strategies to Mitigate Transmission Risk

Strategies to mitigate the risk of HIV transmission through breast milk are essential for protecting the health and well-being of HIV-exposed infants while supporting breastfeeding practices. These strategies encompass a multidimensional approach that involves maternal interventions, infant prophylaxis, adherence to infant feeding guidelines, and supportive services. By implementing comprehensive strategies, healthcare providers can effectively reduce the risk of mother-to-child transmission (MTCT) of HIV while promoting optimal infant health outcomes. Effective ART for HIV-infected mothers is the cornerstone of preventing MTCT of HIV during breastfeeding. Maternal ART suppresses viral load in both blood and breast milk, reducing the concentration of HIV and the risk of transmission to the infant. Initiating maternal ART as early as possible during pregnancy and maintaining viral suppression throughout the breastfeeding period are critical for minimizing transmission risk. Exclusive breastfeeding, where the infant receives only breast milk and no other fluids or foods, is recommended for HIV-infected mothers in resource-limited settings where safe alternatives to breastfeeding are not readily available. Exclusive breastfeeding reduces the risk of HIV transmission compared to mixed feeding practices, which involve supplementation with other fluids or foods. Encouraging exclusive breastfeeding for the first six months of life followed by introduction of complementary foods and continued breastfeeding up to 12 months or longer with appropriate complementary feeding helps maximize the immunological and nutritional benefits of breast milk while minimizing transmission risk.¹²³⁻¹⁴²

Providing antiretroviral prophylaxis to HIV-exposed infants further reduces the risk of HIV acquisition during breastfeeding. Infant prophylaxis with medications such as nevirapine or zidovudine is recommended from birth and continued throughout the breastfeeding period. **Citation**: Obeagu EI, Obeagu GU. Impact of Breastfeeding on Infant Immune Responses in the Context of HIV. Elite Journal of Nursing and Health Science, 2024; 2(4):23-39

Adherence to prescribed infant prophylaxis regimens is essential for achieving optimal protection against HIV transmission. Adherence to infant feeding guidelines recommended by the World Health Organization (WHO) is crucial for reducing transmission risk while supporting optimal infant nutrition and growth. Healthcare providers should counsel HIV-infected mothers on the importance of exclusive breastfeeding, proper breastfeeding techniques, and appropriate complementary feeding practices. Clear communication of infant feeding options and guidance on safe preparation of infant formula for mothers who choose not to breastfeed are essential components of comprehensive infant feeding counseling. Regular monitoring of maternal viral load, infant growth, and feeding practices is essential for assessing transmission risk and ensuring timely intervention. Supportive services, including lactation support, nutritional counseling, psychosocial support, and access to healthcare facilities, play a crucial role in promoting successful breastfeeding and adherence to recommended interventions. Multi-disciplinary care teams involving healthcare providers, lactation consultants, counselors, and community health workers can provide comprehensive support to HIV-infected mothers and their infants throughout the breastfeeding period.¹⁴³⁻¹⁵⁰

Breast Milk Composition and Infant Immune Function

Breast milk is a dynamic biological fluid that provides a myriad of bioactive components essential for infant growth, development, and immune function.¹⁵¹ The composition of breast milk is finely tuned to meet the nutritional and immunological needs of the developing infant, delivering a complex blend of nutrients, antibodies, immune cells, and other bioactive factors. Understanding the composition of breast milk and its impact on infant immune function is essential for promoting optimal health outcomes in breastfed infants, including those born to HIV-infected mothers. One of the key immunological components of breast milk is immunoglobulin A (IgA), particularly secretory IgA (sIgA), which is specifically tailored to provide passive immunity at mucosal surfaces. sIgA antibodies present in breast milk coat the infant's gastrointestinal and respiratory tracts, acting as a barrier to prevent the attachment and invasion of pathogens. By neutralizing microbes and toxins, sIgA plays a crucial role in protecting the infant from infections, particularly those acquired through mucosal surfaces. In addition to IgA, breast milk contains other immunoglobulins such as IgG and IgM, which further contribute to the infant's immune defenses. IgG antibodies transferred from the mother to the infant through breast milk provide systemic immunity and protection against a wide range of pathogens. IgM antibodies, although present in lower concentrations, also contribute to the infant's immune protection during the early postnatal period.

Furthermore, breast milk is rich in cytokines, chemokines, growth factors, and antimicrobial peptides that modulate immune cell function and promote immune development in the infant.¹⁵² Cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF- β) help regulate immune responses and maintain immune homeostasis, while chemokines facilitate immune cell migration and activation. Growth factors such as epidermal growth factor (EGF) and insulin-like growth factor (IGF) support tissue repair and regeneration, promoting the development of a healthy gut mucosa and immune system. The role of breast milk in shaping the infant gut microbiome is also crucial for immune function. Breast milk contains complex carbohydrates **Citation**: Obeagu EI, Obeagu GU. Impact of Breastfeeding on Infant Immune Responses in the Context of HIV. Elite Journal of Nursing and Health Science, 2024; 2(4):23-39

known as human milk oligosaccharides (HMOs), which serve as prebiotics that selectively promote the growth of beneficial gut bacteria, such as Bifidobacteria and Lactobacilli. The establishment of a diverse and stable gut microbiome early in life is essential for immune development, as gut bacteria play a key role in training the infant's immune system and maintaining immune tolerance. Moreover, breast milk contains various immune cells, including lymphocytes, macrophages, and dendritic cells, which provide additional protection against infections and support immune education in the infant. These maternal immune cells educate the infant's immune system, helping to shape its repertoire of immune cells and responses. The transfer of maternal immune cells through breast milk is particularly relevant in the context of HIV-exposed infants, where it may confer additional protection against HIV transmission and other infections.¹⁵³⁻¹⁵⁴

Conclusion

Breast milk is a remarkable biological fluid that provides a wealth of essential nutrients and immunological components crucial for infant growth, development, and immune function. The intricate composition of breast milk, finely tuned by maternal factors and influenced by environmental and physiological factors, delivers a diverse array of bioactive factors that support the infant's immune system from birth and throughout infancy. The immunological properties of breast milk, including antibodies such as secretory IgA, immunoglobulins such as IgG and IgM, cytokines, chemokines, growth factors, antimicrobial peptides, and immune cells, play a pivotal role in shaping the infant's immune responses and protecting against infections. These components act synergistically to provide both passive and active immunity, promoting immune maturation, maintaining immune homeostasis, and fostering tolerance to harmless antigens.

References

- 1. Кісельова М, Моштук О, Григоренко Л, Шлемкевич О. Breastfeeding is the-" Gold Standard" old experience and new scientifically proven benefits. Неонатологія, хірургія та перинатальна медицина. 2022;12(2 (44)):53-58.
- 2. Ames SR, Lotoski LC, Azad MB. Comparing early life nutritional sources and human milk feeding practices: personalized and dynamic nutrition supports infant gut microbiome development and immune system maturation. Gut Microbes. 2023;15(1):2190305.
- 3. Oddy WH. The impact of breastmilk on infant and child health. Breastfeeding Review. 2002;10(3):5-18.
- 4. Lokossou GA, Kouakanou L, Schumacher A, Zenclussen AC. Human breast milk: from food to active immune response with disease protection in infants and mothers. Frontiers in immunology. 2022; 13:849012.
- 5. Martin CR, Ling PR, Blackburn GL. Review of infant feeding: key features of breast milk and infant formula. Nutrients. 2016;8(5):279.
- 6. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
- 7. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023

;3(1):7-12.

https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.

- Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. <u>links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesionsand-cervical-cancer-screening-services-among-HIV-positive-women.pdf</u>.
- 9. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
- Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
- Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2): 1-5.DOI: 10.22192/ijcrms.2023.09.02.001
- 12. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. <u>links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf</u>.
- Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
- 14. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
- 15. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
- 16. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. <u>links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf</u>.
- Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu Emmanuel Ifeanyi and Obeag

<u>https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu</u>

18. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009

- 19. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. <u>links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-</u> Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
- 20. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
- 21. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
- 22. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130. <u>links/645a166f5762c95ac3817d32/Clinical-characteristicsof-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf.</u>
- 23. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3_et_al.IJC RAR.pdf.
- 24. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. <u>links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf</u>
- 25. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
- 26. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
- 27. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. <u>links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf</u>.
- 28. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in

Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134.

https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.

- 29. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
- 30. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
- 31. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. <u>links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virusbased-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.</u>
- 32. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
- 33. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 <u>links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf</u>.
- 34. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_pati ents_coinfected_with_HIV.pdf
- 35. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
- 36. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: DOI: <u>10.32474/JCCM.2020.02.000137</u> <u>links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.</u>

- 37. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
- 38. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
- 39. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Steven PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious Diseases. 2022;10(4):1-7.
- 40. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
- 41. Igwe MC, Obeagu EI, Ogbuabor AO. Analysis of the Factors and Predictors of Adherence to Healthcare of People Living With Hiv/Aids In Tertiary Health Institutions In Enugu State. Madonna University Journal of Medicine and Health Sciences. 2022;2(3):42-57. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75.
- 42. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
- 43. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
- 44. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160. <u>links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf</u>.
- 45. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
- 46. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 <u>links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-onhighly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf</u>.

- Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 <u>links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf</u>.
- 48. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33. <u>links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.</u>
- 49. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910. <u>https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu_U_Getrude_Uzoma.EMMA2.pdf</u>.
- 50. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
- 51. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. International Journal of Medical Science and Dental Research, 2018; 1 (2):08-14. https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on% 20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%2 0Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching %20Hospital.pdf.
- 52. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
- 53. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
- 54. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
- 55. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
- 56. Carr LE, Virmani MD, Rosa F, Munblit D, Matazel KS, Elolimy AA, Yeruva L. Role of human milk bioactives on infants' gut and immune health. Frontiers in immunology. 2021; 12:604080.
- 57. Bardanzellu F, Peroni DG, Fanos V. Human breast milk: bioactive components, from stem cells to health outcomes. Current nutrition reports. 2020; 9:1-3.
- 58. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.

- 59. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
- 60. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.
- 61. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
- 62. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
- 63. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
- 64. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.00000000036599. PMID: 38065920; PMCID: PMC10713174.
- Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.00000000036342. PMID: 38013335; PMCID: PMC10681551.
- 66. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.000000000035910. PMID: 38013350; PMCID: PMC10681510.
- Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.00000000036166. PMID: 37986340; PMCID: PMC10659731.
- 68. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
- 69. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
- Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
- 71. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. Elite Journal of Public Health. 2024;2(1):8-22.
- 72. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology. 2024;2(1):14-33.

- 73. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. Medicine. 2024;103(9): e37354.
- 74. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. Elite Journal of Immunology. 2024;2(1):1-3.
- 75. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. Elite Journal of Immunology. 2024;2(1):34-46.
- 76. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):46-58.
- 77. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. Elite Journal of Medicine. 2024;2(1):35-46.
- 78. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. Journal home page: http://www.journalijiar.com.;12(01).
- 79. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.
- Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Coinfected with Malaria: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
- 81. Obeagu EI, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. Elite Journal of HIV. 2024;2(1):31-50.
- 82. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV. 2024;2(1):1-5.
- 83. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):25-36.
- 84. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Sciences. 2024;4(1):32-7.
- 85. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. Sciences. 2024;4(1):38-44.
- Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. Elite Journal of Health Science. 2024;2(1):33-42.
- 87. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. Elite Journal of Haematology. 2024;2(1):26-41.
- 88. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. Elite Journal of Medicine. 2024;2(2):104-15.
- 89. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology. 2024;2(1):47-64.
- 90. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV. 2024;2(2):1-7.

- 91. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health. 2024;2(1):52-61.
- 92. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. Elite Journal of Public Health. 2024;2(1):22-34.
- 93. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(1):21-31.
- 94. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www.journalijiar.com.;12(01).
- 95. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science. 2024;2(3):38-58.
- 96. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. Elite Journal of HIV. 2024;2(3):14-26.
- 97. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health. 2024;2(1):52-63.
- 98. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):46-58.
- 99. Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. Elite Journal of Scientific Research and Review. 2024;2(1):37-50.
- 100. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.
- 101. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. Elite Journal of Nursing and Health Science. 2024;2(3):59-72.
- 102. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science. 2024;2(2):5-15.
- Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. Elite Journal of Medicine. 2024;2(1):35-46.
- Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV. 2024;2(2):1-7.
- 105. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV. 2024;2(2):60-73.
- 106. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine. 2024;2(1):10-22.
- 107. Obeagu EI, AmaezeAA O, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. Elite Journal of Nursing and Health Science. 2024;2(2):33-46.

- 108. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):11-24.
- Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):25-36.
- 110. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. Elite Journal of Immunology. 2024;2(3):33-44.
- 111. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. Elite Journal of Immunology. 2024;2(2):15-28.
- 112. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. Journal home page: http://www. journalijiar. com.;12(01).
- 113. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. Journal home page: http://www.journalijiar.com.;12(01).
- 114. Obeagu EI, Igwe MC, Obeagu GU. The Power of Unity: Collective Efforts in Confronting HIV Stigma. Elite Journal of Public Health. 2024;2(3):22-36.
- Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV. 2024;2(1):16-30.
- 116. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology. 2024;2(1):47-64.
- 117. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. Elite Journal of Haematology, 2024; 2 (3).:10-24.
- 118. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine. 2024;2(1):33-45.
- 119. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV. 2024;2(1):51-64.
- 120. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):41-51.
- 121. Obeagu EI, Obeagu GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. Elite Journal of Scientific Research and Review. 2024;2(1):24-36.
- 122. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV-Exposed Infants: A Review. Elite Journal of Immunology. 2024;2(3):1-8.
- 123. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV. 2024;2(1):1-5.
- 124. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. Elite Journal of Haematology, 2024; 2 (3).:42-57.
- 125. Obeagu EI, Obeagu GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. Elite Journal of Scientific Research and Review. 2024;2(1):1-6.

- 126. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health. 2024;2(1):52-61.
- 127. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Sciences. 2024;4(1):32-7.
- 128. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. Elite Journal of Health Science. 2024;2(2):16-29.
- 129. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. Sciences. 2024;4(1):38-44.
- 130. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. Elite Journal of Nursing and Health Science. 2024;2(2):1-7.
- 131. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. Elite Journal of Haematology. 2024;2(1):26-41.
- 132. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):9-19.
- 133. Obeagu EI, Obeagu GU. Impact of Blood Transfusion on Viral Load Dynamics in HIV-Positive Neonates with Severe Malaria: A Review. Elite Journal of Scientific Research and Review. 2024;2(1):42-60.
- 134. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. Elite Journal of Medicine. 2024;2(2):104-5.
- 135. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. Elite Journal of Haematology, 2024; 2 (3).:25-41.
- 136. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. Elite Journal of Health Science. 2024;2(1):33-42.
- 137. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. Elite Journal of HIV. 2024;2(2):43-59.
- 138. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. Elite Journal of Health Science. 2024;2(3):23-35.
- Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(1):21-31.
- 140. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(3):84-99.
- 141. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. Elite Journal of Health Science. 2024;2(2):20-35.
- 142. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies. Elite Journal of Laboratory Medicine. 2024;2(2):30-46.

- 143. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.
- 144. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. Elite Journal of Public Health. 2024;2(1):35-51.
- 145. Kalu OA, Ukibe NR, Onyenekwe CC, Okoyeagu RC, Nnaemeka WS, Onyenekwe AJ, Ukibe EG, Ukibe BC, Ukibe VE, Obeagu EI. Assessment of Serum Cystatin C, Microalbumin Levels and Egfr in HIV Seropositive Individuals based on Age and Gender in NAUTH, Nnewi, Nigeria. Elite Journal of Medicine. 2024;2(3):48-59.
- Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. Elite Journal of Immunology. 2024;2(2):43-59.
- Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):14-32.
- 148. Obeagu EI, Obeagu GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review. 2024;2(1):17-41.
- 149. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. Elite Journal of Medicine. 2024;2(1):1-6.
- 150. Obeagu EI, GU EE. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. Elite Journal of Haematology, 2024; 2 (3).:111-7.
- 151. Bardanzellu F, Peroni DG, Fanos V. Human breast milk: bioactive components, from stem cells to health outcomes. Current nutrition reports. 2020; 9:1-3.
- 152. Lepage P, Van de Perre P. The immune system of breast milk: antimicrobial and anti-inflammatory properties. Human Immunodeficiency Virus type 1 (HIV-1) and Breastfeeding: Science, Research Advances, and Policy. 2012:121-137.
- 153. Obeagu EI, Obeagu GU. Anemia in HIV: The Role of Erythropoietin in Disease Progression. *Elite Journal of Haematology*, 2024; 2(4): 51-67
- 154. Obeagu EI, Obeagu GU. ART and Platelet Dynamics: Assessing Implications for HIV Patient Care. *Elite Journal of Haematology*, 2024; 2(4): 68-85